##ANALYSISTYPE=SOMATIC_PAIR
##PIPELINE=megSAP 2022_08-55-g2538d173
##GENOME_BUILD=GRCh38
##CREATION_DATE=2022-10-24
##SAMPLE=<ID=DNA123456_01,Gender=male,ExternalSampleName=DNA-2207370 A1,IsTumor=yes,IsFFPE=yes,DiseaseGroup=n/a,DiseaseStatus=n/a>
##SAMPLE=<ID=NA12878_03,Gender=male,ExternalSampleName=DNA-2108953 A1,IsTumor=no,IsFFPE=no,DiseaseGroup=n/a,DiseaseStatus=n/a>
##DESCRIPTION=filter=Annotations for filtering and ranking variants.
##DESCRIPTION=quality=Quality parameters - variant quality (QUAL), depth (DP), quality divided by depth (QD), allele frequency (AF), mean mapping quality of alternate allele (MQM), probability of strand bias for alternate bases as phred score (SAP), probability of allele ballance as phred score (ABP)
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, ENST number, type, impact, exon/intron number, HGVS.c, HGVS.p, Pfam domain).
##DESCRIPTION=regulatory=Regulatory consequence details.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD project.
##DESCRIPTION=gnomAD_sub=Sub-population allele frequenciens (AFR,AMR,EAS,NFE,SAS) in gnomAD project.
##DESCRIPTION=gnomAD_hom_hemi=Homoyzgous counts and hemizygous counts of gnomAD project (genome data).
##DESCRIPTION=gnomAD_het=Heterozygous counts of the gnomAD project (genome data).
##DESCRIPTION=gnomAD_wt=Wildtype counts of the gnomAD project (genome data).
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=Sift=Sift effect prediction and score for each transcript: D=damaging, T=tolerated.
##DESCRIPTION=PolyPhen=PolyPhen (humVar) effect prediction and score for each transcript: D=probably damaging, P=possibly damaging, B=benign.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 10-20.
##DESCRIPTION=REVEL=REVEL pathogenicity prediction score. Deleterious threshold > 0.5.
##DESCRIPTION=MaxEntScan=MaxEntScan splicing prediction (reference bases score/alternate bases score).
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=SpliceAI=SpliceAI prediction of splice-site variations. Probability of the variant being splice-altering (range from 0-1). The score is the maximum value of acceptor/donor gain/loss of all effected genes.
##DESCRIPTION=PubMed=PubMed ids to publications on the given variant.
##DESCRIPTION=NGSD_som_c=Somatic variant count in the NGSD.
##DESCRIPTION=NGSD_som_p=Project names of project containing this somatic variant in the NGSD.
##DESCRIPTION=NGSD_som_vicc_interpretation=Somatic variant interpretation according VICC standard in the NGSD.
##DESCRIPTION=NGSD_som_vicc_comment=Somatic VICC interpretation comment in the NGSD.
##DESCRIPTION=NGSD_hom=Homozygous variant count in NGSD.
##DESCRIPTION=NGSD_het=Heterozygous variant count in NGSD.
##DESCRIPTION=NGSD_group=Homozygous / heterozygous variant count in NGSD with the same disease group.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validation=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Variant comments from the NGSD.
##DESCRIPTION=gene_info=Gene information from NGSD (inheritance mode, gnomAD o/e scores).
##DESCRIPTION=CMC_genes=Gene symbol from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_MUTATION_ID=COSV identifier of variant from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_disease=diseases with > 1% of samples mutated where disease = Primary site(tissue) / Primary histology / Sub-histology = Samples mutated / Samples tested = Frequency from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_DNDS_ratio=diseases with significant dn/ds ratio (q-value < 5%) from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_mutation_significance=Significance tier of the variant from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CANCERHOTSPOTS_AA_CHANGE=Amino acid change as in original cancerhotspots.org file
##DESCRIPTION=CANCERHOTSPOTS_TOTAL_MUT=Total mutation count in cancerhotspots.org at certain amino acid position.
##DESCRIPTION=CANCERHOTSPOTS_ALT_COUNT=Count of specific amino acid alteration at same position in cancerhotspots.org.
##DESCRIPTION=tumor_af=Mutant allele frequency in tumor (Sample DNA123456_01).
##DESCRIPTION=tumor_dp=Tumor Depth (Sample DNA123456_01).
##DESCRIPTION=normal_af=Mutant allele frequency in normal (Sample NA12878_03).
##DESCRIPTION=normal_dp=Normal depth (Sample NA12878_03).
##DESCRIPTION=somatic_classification_comment=Somatic classification comment from the NGSD.
##DESCRIPTION=somatic_classification=Somatic classification from the NGSD.
##DESCRIPTION=ncg_oncogene=1:gene is oncogene according NCG6.0, 0:No oncogene according NCG6.0, na: no information available about gene in NCG6.0. Order is the same as in column gene.
##DESCRIPTION=ncg_tsg=1:gene is TSG according NCG6.0, 0:No TSG according NCG6.0, na: no information available about gene in NCG6.0. Order is the same as in column gene.
##FILTER=LowDepth=Tumor or normal sample read depth at this locus is below 2
##FILTER=LowEVS=Somatic Empirical Variant Score (SomaticEVS) is below threshold
##FILTER=all-unknown=Allele unknown
##FILTER=depth-nor=Sequencing depth in normal is too low (< 20)
##FILTER=depth-tum=Sequencing depth in tumor is too low (< 20)
##FILTER=freq-nor=Allele frequency in normal > 0.17 * allele frequency in tumor
##FILTER=freq-tum=Allele frequency in tumor < 0.05
##FILTER=low_conf_region=Low confidence region for small variant calling based on gnomAD AC0/RF filters and IMGAG trio/twin data.
##FILTER=lt-3-reads=Less than 3 supporting tumor reads
##FILTER=off-target=Variant marked as 'off-target'.
##FILTER=special-chromosome=Special chromosome
##DESCRIPTION=RNA2207371A1_01_rna_depth=Depth in RNA BAM file /mnt/storage2/GRCh38/projects/diagnostic/SomaticAndTreatment/Sample_RNA2207371A1_01/RNA2207371A1_01.bam
##DESCRIPTION=RNA2207371A1_01_rna_af=Allele frequency in RNA BAM file /mnt/storage2/GRCh38/projects/diagnostic/SomaticAndTreatment/Sample_RNA2207371A1_01/RNA2207371A1_01.bam
##DESCRIPTION=RNA2207371A1_01_rna_tpm=Transcript count as annotated per gene from /mnt/storage2/GRCh38/projects/diagnostic/SomaticAndTreatment/Sample_RNA2207371A1_01/RNA2207371A1_01_counts.tsv
##RNA_REF_TPM_TISSUE=frontal cortex
##DESCRIPTION=rna_ref_tpm=RNA reference data in transcripts per million for tissue frontal cortex from proteinatlas.org.
#chr	start	end	ref	obs	tumor_af	tumor_dp	normal_af	normal_dp	filter	quality	gene	variant_type	coding_and_splicing	regulatory	OMIM	ClinVar	HGMD	RepeatMasker	dbSNP	gnomAD	gnomAD_sub	gnomAD_hom_hemi	gnomAD_het	gnomAD_wt	phyloP	CADD	REVEL	MaxEntScan	COSMIC	SpliceAI	PubMed	NGSD_som_c	NGSD_som_p	NGSD_som_vicc_interpretation	NGSD_som_vicc_comment	NGSD_hom	NGSD_het	NGSD_group	classification	classification_comment	somatic_classification	somatic_classification_comment	validation	comment	gene_info	CMC_genes	CMC_MUTATION_ID	CMC_disease	CMC_DNDS_ratio	CMC_mutation_significance	CANCERHOTSPOTS_AA_CHANGE	CANCERHOTSPOTS_TOTAL_MUT	CANCERHOTSPOTS_ALT_COUNT	ncg_oncogene	ncg_tsg	RNA2207371A1_01_rna_depth	RNA2207371A1_01_rna_af	RNA2207371A1_01_rna_tpm	rna_ref_tpm
chr1	26779222	26779222	A	G	0.0295	580	0	466	freq-tum	QUAL=157	ARID1A	missense	ARID1A:ENST00000324856.13:missense_variant:MODERATE:exon20/20:c.5324A>G:p.Glu1775Gly:,ARID1A:ENST00000374152.7:missense_variant:MODERATE:exon19/19:c.4175A>G:p.Glu1392Gly:,ARID1A:ENST00000430799.7:missense_variant:MODERATE:exon20/20:c.4172A>G:p.Glu1391Gly:,ARID1A:ENST00000457599.6:missense_variant:MODERATE:exon20/20:c.4673A>G:p.Glu1558Gly:		603024_[GENE=ARID1A_PHENOS=Coffin-Siris syndrome 2, 614607 (3), Autosomal dominant]			GA-rich (Low_complexity)							5.7320	22.10	0.06			0		0				0	0	0 / 0							ARID1A (inh=AD oe_syn=1.08 oe_mis=0.70 oe_lof=0.02)									0	1	2	0.00	58.46	7.2
chr1	92229408	92229408	C	T	0.1042	49	0	31	off-target	QUAL=66	C1orf146,ACTBP12	intron,non_coding_transcript_exon	C1orf146:ENST00000370373.2:intron_variant:MODIFIER:intron1/6:c.-447-1974C>T::,C1orf146:ENST00000370375.8:intron_variant:MODIFIER:intron1/5:c.-39-1974C>T::,ACTBP12:ENST00000435871.1:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.28G>A::						rs991433825	0.0001		0,.	2	152168	3.1010	1.78				0		2	Novartis,SomaticAndTreatment			0	1	0 / 0							C1ORF146 (inh=n/a oe_syn=0.74 oe_mis=0.88 oe_lof=0.67), ACTBP12 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)									na,na	na,na	1	0.00	0.00	0.0
chr1	150950737	150950737	G	A	0.0192	995	0	878	freq-tum	QUAL=241	SETDB1	synonymous	SETDB1:ENST00000271640.9:synonymous_variant:LOW:exon13/22:c.1860G>A:p.Lys620=:PF01429 [Methyl-CpG binding domain],SETDB1:ENST00000368969.8:synonymous_variant:LOW:exon13/22:c.1860G>A:p.Lys620=:PF01429 [Methyl-CpG binding domain],SETDB1:ENST00000692827.1:synonymous_variant:LOW:exon13/22:c.1863G>A:p.Lys621=:PF01429 [Methyl-CpG binding domain]												1.2520	7.99			COSV54988883	0		0				0	0	0 / 0							SETDB1 (inh=n/a oe_syn=1.03 oe_mis=0.59 oe_lof=0.11)	SETDB1	COSV54988883			Other				na	na	6	0.17	15.38	4.0
chr1	193236215	193236215	G	A	0.2634	579	0	328	off-target	QUAL=345	CDC73	intron	CDC73:ENST00000367435.5:intron_variant:MODIFIER:intron14/16:c.1317-41G>A::,CDC73:ENST00000635846.1:intron_variant:MODIFIER:intron11/13:c.1074-41G>A::		607393_[GENE=CDC73_PHENOS=Hyperparathyroidism, familial primary, 145000 (3), Autosomal dominant; Parathyroid adenoma with cystic changes, 145001 (3), Autosomal dominant; Parathyroid carcinoma, 608266 (3); Hyperparathyroidism-jaw tumor syndrome, 145001 (3), Autosomal dominant]				rs777174036	0.0001		0,.	4	152168	-1.4350	0.35				0.06		1	SomaticAndTreatment			0	0	0 / 0							CDC73 (inh=AD oe_syn=1.05 oe_mis=0.40 oe_lof=0.07)									0	1	.	.	36.27	3.8
chr1	206493470	206493470	G	A	0.2574	203	0	132	off-target	QUAL=181	C1orf147,IKBKE	intron&non_coding_transcript,intron	C1orf147:ENST00000367119.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron1/1:n.136-394C>T::,IKBKE:ENST00000578328.6:intron_variant:MODIFIER:intron19/20:c.1932+351G>A::,IKBKE:ENST00000581977.7:intron_variant:MODIFIER:intron20/21:c.2045+92G>A::,IKBKE:ENST00000584998.5:intron_variant:MODIFIER:intron19/20:c.1790+92G>A::						rs17024891	0.0609		702,.	7866	142940	-0.6160	0.53			COSV65622954	0		7	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							IKBKE (inh=n/a oe_syn=0.91 oe_mis=0.72 oe_lof=0.29), C1ORF147 (inh=n/a oe_syn=0.78 oe_mis=0.80 oe_lof=1.42)									na,na	na,na	0	0.00	0.00	0.6
chr1	226064368	226064368	A	T	0.2841	816	0	522		QUAL=624	H3-3A	missense	H3-3A:ENST00000366813.1:missense_variant:MODERATE:exon1/3:c.17A>T:p.Gln6Leu:PF00125 [Core histone H2A/H2B/H3/H4],H3-3A:ENST00000366814.3:missense_variant:MODERATE:exon2/3:c.17A>T:p.Gln6Leu:PF00125 [Core histone H2A/H2B/H3/H4],H3-3A:ENST00000366815.10:missense_variant:MODERATE:exon2/4:c.17A>T:p.Gln6Leu:PF00125 [Core histone H2A/H2B/H3/H4],H3-3A:ENST00000366816.5:missense_variant:MODERATE:exon3/5:c.17A>T:p.Gln6Leu:PF00125 [Core histone H2A/H2B/H3/H4],H3-3A:ENST00000655399.1:missense_variant:MODERATE:exon2/4:c.17A>T:p.Gln6Leu:PF00125 [Core histone H2A/H2B/H3/H4],H3-3A:ENST00000661429.1:missense_variant:MODERATE:exon2/4:c.17A>T:p.Gln6Leu:PF00125 [Core histone H2A/H2B/H3/H4],H3-3A:ENST00000666609.1:missense_variant:MODERATE:exon2/4:c.17A>T:p.Gln6Leu:PF00125 [Core histone H2A/H2B/H3/H4],H3-3A:ENST00000667897.1:missense_variant:MODERATE:exon2/4:c.17A>T:p.Gln6Leu:PF00125 [Core histone H2A/H2B/H3/H4]	regulatory_region_variant:promoter	601128_[GENE=H3-3A_PHENOS=Bryant-Li-Bhoj neurodevelopmental syndrome 1, 619720 (3), Autosomal dominant]										9.2490	25.10	0.42		COSV99078291	0.13		1	SomaticAndTreatment	UNCERTAIN_SIGNIFICANCE		0	0	0 / 0							H3-3A-DT (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a), H3-3A (inh=n/a oe_syn=1.08 oe_mis=0.06 oe_lof=0.37)									na	na	12	0.50	22.05	190.9
chr1	227977921	227977921	A	G	0.2105	19	0	15	depth-tum;depth-nor;off-target	QUAL=38	CICP26	non_coding_transcript_exon	CICP26:ENST00000425003.2:non_coding_transcript_exon_variant:MODIFIER:exon1/3:n.273T>C::						rs368368276	0.0012		0,.	175	144927	-1.7060	6.83						40	SomaticAndTreatment			0	95	0 / 1							CICP26 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a), SEPTIN14P17 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)									na	na	1	0.00	0.00	.
chr1	231202225	231202225	T	A	0.1273	92	0	61	LowEVS;off-target;low_conf_region	QUAL=49	TRIM67	intron	TRIM67:ENST00000366653.6:intron_variant:MODIFIER:intron5/9:c.1534+708T>A::,TRIM67:ENST00000444294.7:intron_variant:MODIFIER:intron5/9:c.1528+714T>A::,TRIM67:ENST00000449018.7:intron_variant:MODIFIER:intron7/11:c.1348+708T>A::	regulatory_region_variant:enhancer				GA-rich (Low_complexity)	rs1247052244	0.0280		0,.	97	3369	-0.2800	2.66				0		6	Novartis,SomaticAndTreatment			0	0	0 / 0							TRIM67 (inh=n/a oe_syn=1.02 oe_mis=0.76 oe_lof=0.14)									na	na	.	.	0.57	0.2
chr2	4514583	4514583	C	A	0.0847	60	0	49	off-target	QUAL=69	NPM1P48	non_coding_transcript_exon	NPM1P48:ENST00000436002.1:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.474G>T::					(TCA)n (Simple_repeat)							-0.1760	0.66						0				0	0	0 / 0							NPM1P48 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)									na	na	1	0.00	0.00	.
chr2	29193683	29193683	C	-	0.2128	877	0	803		QUAL=587	ALK,CLIP4	frameshift,intron	ALK:ENST00000389048.8:frameshift_variant:HIGH:exon29/29:c.4404del:p.Pro1469ArgfsTer8:,ALK:ENST00000618119.4:frameshift_variant:HIGH:exon28/28:c.3273del:p.Pro1092ArgfsTer8:,ALK:ENST00000642122.1:frameshift_variant:HIGH:exon10/10:c.1200del:p.Pro401ArgfsTer8:,CLIP4:ENST00000689605.1:intron_variant:MODIFIER:intron16/16:c.1923-3243del::		105590_[GENE=ALK_PHENOS={Neuroblastoma, susceptibility to, 3}, 613014 (3)]										-0.1720					0		0		UNCERTAIN_SIGNIFICANCE		0	0	0 / 0							CLIP4 (inh=n/a oe_syn=0.91 oe_mis=0.93 oe_lof=0.53), ALK (inh=n/a oe_syn=1.17 oe_mis=1.00 oe_lof=0.32)									1,na	0,na	3	0.00	16.73	0.7
chr2	38985716	38985716	T	G	0.2	119	0.0556	117	freq-nor;off-target	QUAL=75	SOS1	3'UTR,intron	SOS1:ENST00000395038.6:3_prime_UTR_variant:MODIFIER:exon22/22:c.*108A>C::,SOS1:ENST00000402219.8:3_prime_UTR_variant:MODIFIER:exon23/23:c.*108A>C::,SOS1:ENST00000685279.1:3_prime_UTR_variant:MODIFIER:exon15/15:c.*108A>C::,SOS1:ENST00000692089.1:intron_variant:MODIFIER:intron21/21:c.3399+1757A>C::		182530_[GENE=SOS1_PHENOS=Noonan syndrome 4, 610733 (3), Autosomal dominant; ?Fibromatosis, gingival, 1, 135300 (3), Autosomal dominant]					0.0001		0,.	2	150102	5.3000	16.85				0		22	SomaticAndTreatment,practical_training			0	22	0 / 6							SOS1 (inh=AD oe_syn=0.99 oe_mis=0.68 oe_lof=0.07)									na	na	5	0.00	26.75	5.7
chr2	47783578	47783578	T	G	0.2571	45	0.0385	54	off-target	QUAL=36	MSH6	intron	MSH6:ENST00000234420.11:intron_variant:MODIFIER:intron1/9:c.260+85T>G::,MSH6:ENST00000540021.6:intron_variant:MODIFIER:intron1/7:c.237+108T>G::,MSH6:ENST00000652107.1:intron_variant:MODIFIER:intron3/11:c.-37-7349T>G::,MSH6:ENST00000673637.1:intron_variant:MODIFIER:intron1/9:c.-38+347T>G::,MSH6:ENST00000700000.1:intron_variant:MODIFIER:intron1/9:c.260+85T>G::,MSH6:ENST00000700002.1:intron_variant:MODIFIER:intron1/9:c.260+85T>G::	regulatory_region_variant:promoter	600678_[GENE=MSH6_PHENOS=Colorectal cancer, hereditary nonpolyposis, type 5, 614350 (3), Autosomal dominant; Mismatch repair cancer syndrome 3, 619097 (3), Autosomal recessive; {Endometrial cancer, familial}, 608089 (3), Somatic mutation, Autosomal dominant]				rs1183862573	0.0018		0,.	201	109281	-2.9560	2.75				0		3	SomaticAndTreatment,WES_ZPM			0	10	0 / 4							MSH6 (inh=AR+AD oe_syn=1.50 oe_mis=1.29 oe_lof=0.34)									0	1	.	.	5.95	6.1
chr2	90397838	90397838	C	G	0.375	9	0	10	depth-tum;depth-nor;off-target;low_conf_region	QUAL=17		intergenic	::intergenic_variant:MODIFIER::::						rs56108571	0.0699		0,.	95	1265	0.0360	13.72						3	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)																na	na	.	.	0.00	.
chr2	140335502	140335502	-	A	0.2267	86	0	51	off-target	QUAL=76	LRP1B	intron	LRP1B:ENST00000389484.8:intron_variant:MODIFIER:intron78/90:c.12116+112dup::																	0		0				0	0	0 / 0							LRP1B (inh=n/a oe_syn=1.11 oe_mis=0.89 oe_lof=0.26)									0	1	.	.	50.51	4.3
chr2	191058085	191058085	G	A	0.0276	440	0	284	freq-tum	QUAL=116	STAT4	missense,intron&non_coding_transcript	STAT4:ENST00000358470.8:missense_variant:MODERATE:exon13/24:c.1139C>T:p.Thr380Ile:PF02864 [STAT protein DNA binding domain],STAT4:ENST00000392320.7:missense_variant:MODERATE:exon13/24:c.1139C>T:p.Thr380Ile:PF02864 [STAT protein DNA binding domain],:ENST00000658263.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron1/1:n.1301-6699G>A::		600558_[GENE=STAT4_PHENOS={Systemic lupus erythematosus, susceptibility to, 11}, 612253 (3)]										6.4200	25.60	0.63		COSV61830553	0.02		0				0	0	0 / 0							STAT4 (inh=n/a oe_syn=0.86 oe_mis=0.61 oe_lof=0.20)	STAT4	COSV61830553			Other				na	na	2	0.00	3.11	5.1
chr2	201284717	201284717	G	T	0.1282	56	0	28	off-target;low_conf_region	QUAL=65	CASP8	intron	CASP8:ENST00000264275.9:intron_variant:MODIFIER:intron8/9:c.854-99G>T::,CASP8:ENST00000323492.11:intron_variant:MODIFIER:intron6/7:c.758-99G>T::,CASP8:ENST00000358485.8:intron_variant:MODIFIER:intron7/8:c.980-99G>T::,CASP8:ENST00000392263.6:intron_variant:MODIFIER:intron7/8:c.758-99G>T::,CASP8:ENST00000413726.6:intron_variant:MODIFIER:intron7/8:c.803-99G>T::,CASP8:ENST00000432109.6:intron_variant:MODIFIER:intron8/9:c.803-99G>T::,CASP8:ENST00000440732.6:intron_variant:MODIFIER:intron8/9:c.803-99G>T::,CASP8:ENST00000444430.3:intron_variant:MODIFIER:intron3/4:c.551-99G>T::,CASP8:ENST00000450491.6:intron_variant:MODIFIER:intron6/7:c.449-99G>T::,CASP8:ENST00000673742.1:intron_variant:MODIFIER:intron7/8:c.803-99G>T::,CASP8:ENST00000696067.1:intron_variant:MODIFIER:intron8/9:c.803-99G>T::,CASP8:ENST00000696069.1:intron_variant:MODIFIER:intron5/6:c.758-99G>T::,CASP8:ENST00000696085.1:intron_variant:MODIFIER:intron6/7:c.935-99G>T::,CASP8:ENST00000696087.1:intron_variant:MODIFIER:intron6/7:c.758-99G>T::		601763_[GENE=CASP8_PHENOS={Breast cancer, protection against}, 114480 (3), Somatic mutation, Autosomal dominant; ?Caspase 8 lymphadenopathy syndrome, 607271 (3), Autosomal recessive; Hepatocellular carcinoma, somatic, 114550 (3); {Lung cancer, protection against}, 211980 (3), Somatic mutation, Autosomal dominant]				rs113659856	0.0002		0,.	5	23153	-0.4900	7.88				0		57	Novartis,SomaticAndTreatment,Twist_Exome_Test,practical_training			190	52	34 / 8							CASP8 (inh=AR+AD oe_syn=0.95 oe_mis=0.83 oe_lof=0.51), FLACC1 (inh=n/a oe_syn=1.01 oe_mis=1.04 oe_lof=1.09)									0	1	.	.	3.62	0.6
chr2	232111095	232111095	A	C	0.0493	145	0	80	LowEVS;freq-tum;off-target	QUAL=71	DIS3L2	intron	DIS3L2:ENST00000273009.10:intron_variant:MODIFIER:intron6/13:c.602-19524A>C::,DIS3L2:ENST00000325385.12:intron_variant:MODIFIER:intron6/20:c.602-19524A>C::,DIS3L2:ENST00000409401.7:intron_variant:MODIFIER:intron6/6:c.602-19524A>C::		614184_[GENE=DIS3L2_PHENOS=Perlman syndrome, 267000 (3), Autosomal recessive]										-0.9090	0.10				0		0				0	0	0 / 0							DIS3L2 (inh=AR oe_syn=1.01 oe_mis=0.89 oe_lof=0.18)									na	na	.	.	8.35	4.5
chr3	10046914	10046914	-	C	0.1481	33	0	26	off-target	QUAL=48	FANCD2	intron	FANCD2:ENST00000287647.7:intron_variant:MODIFIER:intron15/42:c.1278+191_1278+192insC::,FANCD2:ENST00000419585.5:intron_variant:MODIFIER:intron15/43:c.1278+191_1278+192insC::,FANCD2:ENST00000675286.1:intron_variant:MODIFIER:intron15/43:c.1278+191_1278+192insC::		613984_[GENE=FANCD2_PHENOS=Fanconi anemia, complementation group D2, 227646 (3), Autosomal recessive]			L3 (LINE/CR1)	rs142887274	0.4618		0,.	67896	79136		2.36				0		15	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							FANCD2 (inh=AR oe_syn=0.96 oe_mis=1.00 oe_lof=0.71)									0	1	.	.	7.53	0.1
chr3	10046952	10046952	G	A	0.25	12	0	14	depth-tum;depth-nor;off-target	QUAL=32	FANCD2	intron	FANCD2:ENST00000287647.7:intron_variant:MODIFIER:intron15/42:c.1278+229G>A::,FANCD2:ENST00000419585.5:intron_variant:MODIFIER:intron15/43:c.1278+229G>A::,FANCD2:ENST00000675286.1:intron_variant:MODIFIER:intron15/43:c.1278+229G>A::		613984_[GENE=FANCD2_PHENOS=Fanconi anemia, complementation group D2, 227646 (3), Autosomal recessive]				rs78628790	0.4589		0,.	63238	74568	0.3360	8.16				0		30	SomaticAndTreatment,practical_training			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							FANCD2 (inh=AR oe_syn=0.96 oe_mis=1.00 oe_lof=0.71)									0	1	.	.	7.53	0.1
chr3	48575925	48575925	G	A	0.0293	311	0	318	freq-tum;off-target	QUAL=124	COL7A1	intron	COL7A1:ENST00000328333.12:intron_variant:MODIFIER:intron70/117:c.5821-23C>T::,COL7A1:ENST00000681320.1:intron_variant:MODIFIER:intron71/118:c.5821-23C>T::		120120_[GENE=COL7A1_PHENOS=EBD, localisata variant (3); Epidermolysis bullosa, pretibial, 131850 (3), Autosomal recessive, Autosomal dominant; Transient bullous of the newborn, 131705 (3), Autosomal recessive, Autosomal dominant; EBD, Bart type, 132000 (3), Autosomal dominant; Epidermolysis bullosa dystrophica, AD, 131750 (3), Autosomal dominant; Epidermolysis bullosa pruriginosa, 604129 (3), Autosomal recessive, Autosomal dominant; EBD inversa, 226600 (3), Autosomal recessive; Epidermolysis bullosa dystrophica, AR, 226600 (3), Autosomal recessive; Toenail dystrophy, isolated, 607523 (3), Autosomal dominant]										-0.1350	4.61				0.09		0				0	0	0 / 0							COL7A1 (inh=AR+AD oe_syn=0.98 oe_mis=0.89 oe_lof=0.50), MIR711 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)									na	na	.	.	1.69	0.2
chr3	152340404	152340404	C	T	0.0168	301	0	102	freq-tum;off-target	QUAL=34	MBNL1,TMEM14EP	intron,non_coding_transcript_exon	MBNL1:ENST00000282486.10:intron_variant:MODIFIER:intron2/9:c.174+40037C>T::,MBNL1:ENST00000282488.11:intron_variant:MODIFIER:intron2/10:c.174+40037C>T::,MBNL1:ENST00000324196.9:intron_variant:MODIFIER:intron1/7:c.174+40037C>T::,MBNL1:ENST00000324210.10:intron_variant:MODIFIER:intron2/9:c.174+40037C>T::,MBNL1:ENST00000355460.6:intron_variant:MODIFIER:intron2/8:c.174+40037C>T::,MBNL1:ENST00000357472.7:intron_variant:MODIFIER:intron1/7:c.174+40037C>T::,MBNL1:ENST00000463374.5:intron_variant:MODIFIER:intron1/8:c.174+40037C>T::,MBNL1:ENST00000465907.6:intron_variant:MODIFIER:intron1/6:c.174+40037C>T::,MBNL1:ENST00000485509.5:intron_variant:MODIFIER:intron1/6:c.174+40037C>T::,MBNL1:ENST00000485910.5:intron_variant:MODIFIER:intron1/6:c.174+40037C>T::,MBNL1:ENST00000492948.5:intron_variant:MODIFIER:intron1/6:c.174+40037C>T::,MBNL1:ENST00000493459.5:intron_variant:MODIFIER:intron2/11:c.-56+5174C>T::,MBNL1:ENST00000498502.5:intron_variant:MODIFIER:intron1/7:c.174+40037C>T::,MBNL1:ENST00000545754.5:intron_variant:MODIFIER:intron1/7:c.174+40037C>T::,TMEM14EP:ENST00000639378.1:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.587G>A::						rs1183055393						-0.4930	0.28				0		0				0	0	0 / 0							MBNL1 (inh=n/a oe_syn=0.94 oe_mis=0.50 oe_lof=0.19), TMEM14EP (inh=n/a oe_syn=0.88 oe_mis=0.96 oe_lof=n/a)									na,na	na,na	13	0.08	70.81	13.3
chr4	49120285	49120285	C	T	0.3333	9	0	10	depth-tum;depth-nor;off-target;low_conf_region	QUAL=17		intergenic	::intergenic_variant:MODIFIER::::					(CATTC)n (Satellite)	rs751174036	0.0022		0,.	186	84792		11.61						4	SomaticAndTreatment			0	16	0 / 0																na	na	.	.	0.00	.
chr4	49657570	49657570	G	C	0.1176	27	0	41	LowEVS;off-target	QUAL=44		intergenic	::intergenic_variant:MODIFIER::::					(TGGAA)n (Simple_repeat)								9.17						5	Novartis,SomaticAndTreatment			0	0	0 / 0																na	na	.	.	0.00	.
chr5	1295135	1295135	G	A	0.2063	71	0	57		QUAL=92	TERT	upstream_gene	TERT:ENST00000310581.10:upstream_gene_variant:MODIFIER::::,TERT:ENST00000334602.10:upstream_gene_variant:MODIFIER::::	regulatory_region_variant:promoter	187270_[GENE=TERT_PHENOS=Dyskeratosis congenita, autosomal dominant 2, 613989 (3), Autosomal recessive, Autosomal dominant; Dyskeratosis congenita, autosomal recessive 4, 613989 (3), Autosomal recessive, Autosomal dominant; {Melanoma, cutaneous malignant, 9}, 615134 (3); Pulmonary fibrosis and/or bone marrow failure, telomere-related, 1, 614742 (3), Autosomal dominant; {Leukemia, acute myeloid}, 601626 (3), Somatic mutation, Autosomal dominant]				rs1561215364						0.4200	8.68						215	20101I_0461_Stephan,Novartis,SomaticAndTreatment,practical_training	ONCOGENIC	c.-146C>T	0	1	0 / 0			activating	[activating] ahgscha1 17.01.2020		"c.-146C>T"	TERT (inh=AR+AD oe_syn=0.98 oe_mis=0.49 oe_lof=0.16)									0	0	0	0.00	0.97	0.0
chr5	31529091	31529091	C	T	0.3049	411	0	300	off-target	QUAL=404	DROSHA	5'UTR	DROSHA:ENST00000344624.8:5_prime_UTR_variant:MODIFIER:exon4/36:c.-32G>A::,DROSHA:ENST00000511367.6:5_prime_UTR_variant:MODIFIER:exon3/35:c.-32G>A::,DROSHA:ENST00000513349.5:5_prime_UTR_variant:MODIFIER:exon4/35:c.-32G>A::												0.8490	10.30				0		1	SomaticAndTreatment			0	0	0 / 0							DROSHA (inh=n/a oe_syn=0.93 oe_mis=0.60 oe_lof=0.24), C5ORF22 (inh=n/a oe_syn=0.95 oe_mis=0.96 oe_lof=0.45)									0	1	15	0.53	36.63	2.6
chr5	38990826	38990834	GATATATGA	-	0.2917	21	0	10	depth-nor;off-target;low_conf_region	QUAL=2	RICTOR	intron	RICTOR:ENST00000296782.9:intron_variant:MODIFIER:intron7/38:c.583+115_583+123del::,RICTOR:ENST00000357387.8:intron_variant:MODIFIER:intron7/37:c.583+115_583+123del::						rs137933047	0.0002		0,.	4	20616	0.3620	0.73				0		5	SomaticAndTreatment,Validation_ssSC			1	54	0 / 3							RICTOR (inh=n/a oe_syn=0.91 oe_mis=0.71 oe_lof=0.09)									na	na	.	.	28.13	4.9
chr5	112792446	112792446	C	T	0.2209	88	0	55		QUAL=100	APC	stop_gained&splice_region,intron	APC:ENST00000509732.6:stop_gained&splice_region_variant:HIGH:exon7/16:c.646C>T:p.Arg216Ter:,APC:ENST00000507379.6:intron_variant:MODIFIER:intron5/13:c.676-8833C>T::,APC:ENST00000257430.9:stop_gained&splice_region_variant:HIGH:exon7/16:c.646C>T:p.Arg216Ter:,APC:ENST00000504915.3:stop_gained&splice_region_variant:HIGH:exon7/17:c.646C>T:p.Arg216Ter:,APC:ENST00000508376.6:stop_gained&splice_region_variant:HIGH:exon8/17:c.646C>T:p.Arg216Ter:,APC:ENST00000512211.7:stop_gained&splice_region_variant:HIGH:exon7/16:c.646C>T:p.Arg216Ter:		611731_[GENE=APC_PHENOS=Colorectal cancer, somatic, 114500 (3); Brain tumor-polyposis syndrome 2, 175100 (3), Autosomal dominant; Desmoid disease, hereditary, 135290 (3), Autosomal dominant; Adenoma, periampullary, somatic, 175100 (3); Hepatoblastoma, somatic, 114550 (3); Gastric cancer, somatic, 613659 (3); Gastric adenocarcinoma and proximal polyposis of the stomach, 619182 (3), Autosomal dominant; Gardner syndrome, 175100 (3), Autosomal dominant; Adenomatous polyposis coli, 175100 (3), Autosomal dominant]	127312 [pathogenic DISEASE=Familial adenomatous polyposis 1,Neoplasm of stomach,Carcinoma of colon,Hepatocellular carcinoma,Desmoid disease, hereditary,not provided,Familial multiple polyposis syndrome,Hereditary cancer-predisposing syndrome];	CM992133 [CLASS=DM MUT=ALT PHEN="Adenomatous polyposis coli" GENE=APC];		rs62619935	0.00001	0.00002,0.00000,0.00000,0.00000,0.00000	0,	1	151783	0.685	37.00		8.2>7.8/8.2>7.8/0.0>0.0,/8.2>7.8/0.0>0.0	COSV57320867	0		6	Novartis,SomaticAndTreatment	ONCOGENIC		0	1	0 / 1	5	"[5] ahulagv1 01.12.2023;   PVS1, PS3, PM1, PP3 "	inactivating	[inactivating] aharmes1 17.11.2020		"PVS1, PS3, PM1, PP3"	APC (inh=AD oe_syn=1.11 oe_mis=0.99 oe_lof=0.10)	APC	COSV57320867	large_intestine/carcinoma/adenocarcinoma=122/11687=1.04%	colon=2.67e-06	1				0	1	3	0.33	33.48	6.7
chr5	112840069	112840069	C	-	0.5463	380	0	114		QUAL=301	APC	frameshift	APC:ENST00000509732.6:frameshift_variant:HIGH:exon16/16:c.4476del:p.Thr1493ArgfsTer14:,APC:ENST00000507379.6:frameshift_variant:HIGH:exon14/14:c.4422del:p.Thr1475ArgfsTer14:,APC:ENST00000257430.9:frameshift_variant:HIGH:exon16/16:c.4476del:p.Thr1493ArgfsTer14:,APC:ENST00000504915.3:frameshift_variant:HIGH:exon17/17:c.4530del:p.Thr1511ArgfsTer14:,APC:ENST00000508376.6:frameshift_variant:HIGH:exon17/17:c.4476del:p.Thr1493ArgfsTer14:,APC:ENST00000512211.7:frameshift_variant:HIGH:exon16/16:c.4476del:p.Thr1493ArgfsTer14:		611731_[GENE=APC_PHENOS=Colorectal cancer, somatic, 114500 (3); Brain tumor-polyposis syndrome 2, 175100 (3), Autosomal dominant; Desmoid disease, hereditary, 135290 (3), Autosomal dominant; Adenoma, periampullary, somatic, 175100 (3); Hepatoblastoma, somatic, 114550 (3); Gastric cancer, somatic, 613659 (3); Gastric adenocarcinoma and proximal polyposis of the stomach, 619182 (3), Autosomal dominant; Gardner syndrome, 175100 (3), Autosomal dominant; Adenomatous polyposis coli, 175100 (3), Autosomal dominant]	2583709 [pathogenic DISEASE=Familial adenomatous polyposis 1];									7.568			/0.0>0.0/0.0>0.0	COSV57375363	0		0		ONCOGENIC	Cosmic n=29	0	0	0 / 0							APC (inh=AD oe_syn=1.11 oe_mis=0.99 oe_lof=0.10)	APC	COSV57324116			3				0	1	12	0.42	33.48	6.7
chr5	112843351	112843351	G	T	0.1042	192	0	65		QUAL=81	APC	missense	APC:ENST00000509732.6:missense_variant:MODERATE:exon16/16:c.7757G>T:p.Ser2586Ile:,APC:ENST00000507379.6:missense_variant:MODERATE:exon14/14:c.7703G>T:p.Ser2568Ile:,APC:ENST00000257430.9:missense_variant:MODERATE:exon16/16:c.7757G>T:p.Ser2586Ile:,APC:ENST00000504915.3:missense_variant:MODERATE:exon17/17:c.7811G>T:p.Ser2604Ile:,APC:ENST00000508376.6:missense_variant:MODERATE:exon17/17:c.7757G>T:p.Ser2586Ile:,APC:ENST00000512211.7:missense_variant:MODERATE:exon16/16:c.7757G>T:p.Ser2586Ile:		611731_[GENE=APC_PHENOS=Colorectal cancer, somatic, 114500 (3); Brain tumor-polyposis syndrome 2, 175100 (3), Autosomal dominant; Desmoid disease, hereditary, 135290 (3), Autosomal dominant; Adenoma, periampullary, somatic, 175100 (3); Hepatoblastoma, somatic, 114550 (3); Gastric cancer, somatic, 613659 (3); Gastric adenocarcinoma and proximal polyposis of the stomach, 619182 (3), Autosomal dominant; Gardner syndrome, 175100 (3), Autosomal dominant; Adenomatous polyposis coli, 175100 (3), Autosomal dominant]	41537 [uncertain significance DISEASE=Hereditary cancer-predisposing syndrome,not provided,Familial adenomatous polyposis 1,Gastric adenocarcinoma and proximal polyposis of the stomach,Stomach cancer,Desmoid disease, hereditary,Hepatocellular carcinoma,Colorectal cancer];			rs199806334						7.524	26.50	0.50	/0.0>0.0/4.4>0.0		0		0		UNCERTAIN_SIGNIFICANCE		0	1	0 / 0							APC (inh=AD oe_syn=1.11 oe_mis=0.99 oe_lof=0.10)									0	1	11	0.36	33.48	6.7
chr5	123023808	123023809	AC	-	0.1957	74	0	38	LowEVS;low_conf_region	QUAL=54	PPIC	3'UTR	PPIC:ENST00000306442.5:3_prime_UTR_variant:MODIFIER:exon5/5:c.*66_*67del::					(AC)n (Simple_repeat)	rs70988555	0.0336		79,.	4705	139783	1.4740	2.52				0		1	SomaticAndTreatment			89	1123	11 / 122	2	"[2] auto-classification 30.10.2017  "					RN7SL689P (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a), PPIC (inh=n/a oe_syn=0.97 oe_mis=0.98 oe_lof=0.77)									na	na	63	0.13	20.26	3.3
chr5	150061434	150061434	C	G	0.6	35	0	39	LowEVS;off-target	QUAL=16	CSF1R	intron	CSF1R:ENST00000286301.7:intron_variant:MODIFIER:intron13/21:c.1858+57G>C::,CSF1R:ENST00000675795.1:intron_variant:MODIFIER:intron12/20:c.1858+57G>C::		164770_[GENE=CSF1R_PHENOS=Brain abnormalities, neurodegeneration, and dysosteosclerosis, 618476 (3), Autosomal recessive; Leukoencephalopathy, diffuse hereditary, with spheroids 1, 221820 (3), Autosomal dominant]					0.0001		0,.	1	144621	0.2070	5.37				0		0				0	1	0 / 1							CSF1R (inh=AR+AD oe_syn=1.04 oe_mis=0.81 oe_lof=0.24)									1	0	.	.	51.21	3.5
chr6	29792913	29792913	G	A	0.4688	34	0	21	off-target	QUAL=45	HLA-V	intron&non_coding_transcript,non_coding_transcript_exon	HLA-V:ENST00000429037.2:intron_variant&non_coding_transcript_variant:MODIFIER:intron2/2:n.343-32G>A::,HLA-V:ENST00000446817.1:non_coding_transcript_exon_variant:MODIFIER:exon4/4:n.659G>A::,HLA-V:ENST00000457107.5:intron_variant&non_coding_transcript_variant:MODIFIER:intron2/2:n.353+207G>A::,HLA-V:ENST00000476601.5:intron_variant&non_coding_transcript_variant:MODIFIER:intron2/2:n.670+207G>A::	regulatory_region_variant:promoter				G-rich (Low_complexity)							0.2540	8.61						1	SomaticAndTreatment			0	0	0 / 0							HLA-V (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a), HCG4 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)									na	na	1	0.00	0.43	.
chr6	31575920	31575920	G	A	0.0286	283	0	204	freq-tum	QUAL=91	TNF	missense	TNF:ENST00000449264.3:missense_variant:MODERATE:exon1/4:c.179G>A:p.Arg60Lys:,TNF:ENST00000699334.1:missense_variant:MODERATE:exon1/3:c.179G>A:p.Arg60Lys:	regulatory_region_variant:promoter	153440_[GENE=LTA_PHENOS={Psoriatic arthritis, susceptibility to}, 607507 (3); {Myocardial infarction, susceptibility to}, 608446 (3); {Leprosy, susceptibility to, 4}, 610988 (3)]&191160_[GENE=TNF_PHENOS={Migraine without aura, susceptibility to}, 157300 (3), Autosomal dominant; {Dementia, vascular, susceptibility to} (3); {Asthma, susceptibility to}, 600807 (3), Autosomal dominant; {Septic shock, susceptibility to} (3); {Malaria, cerebral, susceptibility to}, 611162 (3)]										-0.0900	10.76	0.07			0		0				0	0	0 / 0							LTA (inh=n/a oe_syn=0.74 oe_mis=0.52 oe_lof=0.30), TNF (inh=AD oe_syn=0.86 oe_mis=0.61 oe_lof=0.10), LTB (inh=n/a oe_syn=1.01 oe_mis=0.81 oe_lof=1.45)									na	na	2	0.00	5.37	0.0
chr6	93356930	93356930	G	A	0.0245	951	0	751	freq-tum	QUAL=216	EPHA7	missense	EPHA7:ENST00000369303.9:missense_variant:MODERATE:exon5/17:c.1111C>T:p.Arg371Trp:PF00041 [Fibronectin type III domain],EPHA7:ENST00000679565.1:missense_variant:MODERATE:exon5/10:c.1111C>T:p.Arg371Trp:PF00041 [Fibronectin type III domain],EPHA7:ENST00000680190.1:missense_variant:MODERATE:exon5/17:c.883C>T:p.Arg295Trp:PF00041 [Fibronectin type III domain],EPHA7:ENST00000680224.1:missense_variant:MODERATE:exon5/17:c.1111C>T:p.Arg371Trp:PF00041 [Fibronectin type III domain],EPHA7:ENST00000680953.1:missense_variant:MODERATE:exon5/10:c.883C>T:p.Arg295Trp:PF00041 [Fibronectin type III domain],EPHA7:ENST00000681532.1:missense_variant:MODERATE:exon5/10:c.1111C>T:p.Arg371Trp:PF00041 [Fibronectin type III domain]						rs371089003	0.0001		0,.	2	152074	2.7810	27.90	0.44		COSV65181884,COSV65190033	0.46		0				0	3	0 / 0							EPHA7 (inh=n/a oe_syn=1.04 oe_mis=0.71 oe_lof=0.04)	EPHA7	COSV65181884			Other				0	0	4	0.00	2.41	0.5
chr6	137871120	137871120	A	G	0.0611	134	0	53	off-target	QUAL=66	TNFAIP3	intron	TNFAIP3:ENST00000237289.8:intron_variant:MODIFIER:intron1/8:c.-15-93A>G::,TNFAIP3:ENST00000421450.2:intron_variant:MODIFIER:intron1/8:c.-15-93A>G::,TNFAIP3:ENST00000433680.2:intron_variant:MODIFIER:intron1/8:c.-15-93A>G::,TNFAIP3:ENST00000612899.5:intron_variant:MODIFIER:intron1/8:c.-15-93A>G::	regulatory_region_variant:promoter,regulatory_region_variant:CTCF_binding_site	191163_[GENE=TNFAIP3_PHENOS=Autoinflammatory syndrome, familial, Behcet-like 1, 616744 (3), Autosomal dominant]				rs1190208681	0.0001		0,.	1	152077	1.0690	16.84				0.01		0				0	0	0 / 0							WAKMAR2 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a), TNFAIP3 (inh=AD oe_syn=0.85 oe_mis=0.81 oe_lof=0.06)									0	1	.	.	42.41	1.0
chr6	138953682	138953683	AA	-	0.8333	7	0	2	depth-tum;depth-nor;off-target	QUAL=1	REPS1	intron	REPS1:ENST00000258062.9:intron_variant:MODIFIER:intron1/19:c.154-5770_154-5769del::,REPS1:ENST00000367663.8:intron_variant:MODIFIER:intron1/18:c.154-5770_154-5769del::,REPS1:ENST00000409812.6:intron_variant:MODIFIER:intron1/16:c.154-5770_154-5769del::,REPS1:ENST00000415951.6:intron_variant:MODIFIER:intron1/17:c.154-5770_154-5769del::,REPS1:ENST00000450536.7:intron_variant:MODIFIER:intron1/19:c.154-5770_154-5769del::,REPS1:ENST00000626459.2:intron_variant:MODIFIER:intron1/16:c.154-5770_154-5769del::	regulatory_region_variant:enhancer	614825_[GENE=REPS1_PHENOS=?Neurodegeneration with brain iron accumulation 7, 617916 (3), Autosomal recessive]			L1MA5A (LINE/L1)	rs34741005	0.2044		2353,.	21205	100845	-0.5080	0.26				0		2	Novartis,SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							REPS1 (inh=AR oe_syn=0.91 oe_mis=0.77 oe_lof=0.16)									na	na	.	.	39.41	14.3
chr7	24125217	24125217	C	A	0.234	48	0	23	off-target	QUAL=74		intergenic	::intergenic_variant:MODIFIER::::					L1MC4 (LINE/L1)							-0.0500	1.32						0				0	0	0 / 0																na	na	.	.	0.00	.
chr7	39796734	39796734	G	A	0.25	21	0.037	27	LowEVS;off-target	QUAL=32	CICP22	non_coding_transcript_exon	CICP22:ENST00000432801.1:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1178C>T::	regulatory_region_variant:CTCF_binding_site					rs866529427	0.0290		0,.	3615	121185	-0.7670	2.39						4	SomaticAndTreatment			0	52	0 / 8							LINC00265 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a), CICP22 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)									na	na	1	0.00	0.00	.
chr7	55151614	55151614	C	G	0.9722	110	0.3333	3	depth-nor;freq-nor;off-target	QUAL=62	EGFR	intron	EGFR:ENST00000275493.7:intron_variant:MODIFIER:intron5/27:c.628+252C>G::,EGFR:ENST00000342916.7:intron_variant:MODIFIER:intron5/15:c.628+252C>G::,EGFR:ENST00000344576.7:intron_variant:MODIFIER:intron5/15:c.628+252C>G::,EGFR:ENST00000420316.6:intron_variant:MODIFIER:intron5/9:c.628+252C>G::,EGFR:ENST00000450046.2:intron_variant:MODIFIER:intron5/27:c.469+252C>G::,EGFR:ENST00000455089.5:intron_variant:MODIFIER:intron4/25:c.493+252C>G::		131550_[GENE=EGFR_PHENOS=?Inflammatory skin and bowel disease, neonatal, 2, 616069 (3), Autosomal recessive; Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, 211980 (3), Somatic mutation, Autosomal dominant; Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, 211980 (3), Somatic mutation, Autosomal dominant; {Nonsmall cell lung cancer, susceptibility to}, 211980 (3), Somatic mutation, Autosomal dominant]	1288886 [benign DISEASE=not provided];		AluY (SINE/Alu)	rs2075111	0.5091		19786,.	37769	74591	-1.3300	1.02				0	28510291	1	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							EGFR (inh=AR+AD oe_syn=1.13 oe_mis=0.80 oe_lof=0.23)									1	0	.	.	567.06	3.1
chr7	55191822	55191822	T	G	0.1588	450	0	181		QUAL=167	EGFR	missense	EGFR:ENST00000275493.7:missense_variant:MODERATE:exon21/28:c.2573T>G:p.Leu858Arg:,EGFR:ENST00000455089.5:missense_variant:MODERATE:exon20/26:c.2438T>G:p.Leu813Arg:,EGFR:ENST00000450046.2:missense_variant:MODERATE:exon21/28:c.2414T>G:p.Leu805Arg:		131550_[GENE=EGFR_PHENOS=?Inflammatory skin and bowel disease, neonatal, 2, 616069 (3), Autosomal recessive; Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, 211980 (3), Somatic mutation, Autosomal dominant; Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, 211980 (3), Somatic mutation, Autosomal dominant; {Nonsmall cell lung cancer, susceptibility to}, 211980 (3), Somatic mutation, Autosomal dominant]	16609 [drug response DISEASE=Lung cancer,Non-small cell lung carcinoma,Erlotinib response,Gefitinib response,Lung carcinoma,Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, somatic,Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, somatic,Lung adenocarcinoma,Tyrosine kinase inhibitor response,gefitinib response - Efficacy];	CM2111759 [CLASS=DM? MUT=ALT PHEN="Lung cancer" GENE=EGFR];		rs121434568						7.9600	32.00	0.96	/0.0>0.0/0.0>0.0	COSV51765161,COSV51854030	0		3	SomaticAndTreatment	ONCOGENIC	COSMIC%20Recurrence%20%3E%202700%0AOncoKB%20Hotspot	0	0	0 / 0			activating	[activating] aharmes1 13.08.2020			EGFR (inh=AR+AD oe_syn=1.13 oe_mis=0.80 oe_lof=0.23), EGFR-AS1 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)	EGFR	COSV51765161	lung/carcinoma/acinar_adenocarcinoma=4/394=1.02%;lung/carcinoma/adenocarcinoma=1588/50752=3.13%;lung/carcinoma/bronchioloalveolar_adenocarcinoma=80/973=8.22%;lung/carcinoma/mixed_adenosquamous_carcinoma=31/818=3.79%;lung/carcinoma/non_small_cell_carcinoma=854/37521=2.28%;lung/carcinoma/sarcomatoid_carcinoma=7/501=1.4%;lung/other/hyperplasia=8/158=5.06%	NSCLC=3.8e-54	1				1	0	174	0.21	377.01	14.9
chr7	87545987	87545987	C	T	0.0486	540	0	319	freq-tum	QUAL=124	ABCB1	missense	ABCB1:ENST00000265724.8:missense_variant:MODERATE:exon16/29:c.1763G>A:p.Arg588His:,ABCB1:ENST00000543898.5:missense_variant:MODERATE:exon15/28:c.1571G>A:p.Arg524His:,ABCB1:ENST00000622132.5:missense_variant:MODERATE:exon15/28:c.1763G>A:p.Arg588His:		171050_[GENE=ABCB1_PHENOS={Inflammatory bowel disease 13}, 612244 (3); {Colchicine resistance}, 120080 (3)]										6.1780	24.20	0.81		COSV104379009	0.07		2	SomaticAndTreatment	UNCERTAIN_SIGNIFICANCE		0	0	0 / 0							ABCB1 (inh=AD oe_syn=1.02 oe_mis=0.85 oe_lof=0.33)	ABCB1	COSV104379009			Other				na	na	1	0.00	4.85	6.1
chr9	8454812	8454815	GTGT	-	1	9	0	8	depth-tum;depth-nor;off-target	QUAL=1	PTPRD	intron	PTPRD:ENST00000355233.9:intron_variant:MODIFIER:intron17/30:c.2643-221_2643-218del::,PTPRD:ENST00000356435.9:intron_variant:MODIFIER:intron22/34:c.3876-4978_3876-4975del::,PTPRD:ENST00000381196.9:intron_variant:MODIFIER:intron33/45:c.3876-4978_3876-4975del::,PTPRD:ENST00000397606.7:intron_variant:MODIFIER:intron15/28:c.2613-4978_2613-4975del::,PTPRD:ENST00000397611.7:intron_variant:MODIFIER:intron16/29:c.2634-224_2634-221del::,PTPRD:ENST00000397617.8:intron_variant:MODIFIER:intron15/28:c.2622-4978_2622-4975del::,PTPRD:ENST00000486161.5:intron_variant:MODIFIER:intron17/30:c.2643-224_2643-221del::,PTPRD:ENST00000537002.5:intron_variant:MODIFIER:intron16/28:c.2628-4978_2628-4975del::,PTPRD:ENST00000540109.5:intron_variant:MODIFIER:intron22/35:c.3876-4978_3876-4975del::					(GT)n (Simple_repeat)	rs3043784	0.3181		7311,.	32574	101156	0.4260	0.86				0		3	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							PTPRD (inh=n/a oe_syn=1.36 oe_mis=0.98 oe_lof=0.05)									0	1	.	.	53.53	7.8
chr9	20363379	20363379	T	G	0.2273	125	0.0595	190	freq-nor;off-target	QUAL=74	MLLT3	intron	MLLT3:ENST00000380321.5:intron_variant:MODIFIER:intron3/6:c.113+97A>C::,MLLT3:ENST00000380338.9:intron_variant:MODIFIER:intron7/10:c.1331+97A>C::,MLLT3:ENST00000629733.3:intron_variant:MODIFIER:intron3/5:c.113+97A>C::,MLLT3:ENST00000630269.2:intron_variant:MODIFIER:intron7/10:c.1322+97A>C::							0.0000		0,.	0	151452	-0.3230	0.35				0		9	Novartis,SomaticAndTreatment			0	21	0 / 3							MLLT3 (inh=n/a oe_syn=1.32 oe_mis=0.69 oe_lof=0.00)									0	0	.	.	5.78	5.9
chr9	84686398	84686398	C	T	0.0143	992	0.0017	588	freq-tum	QUAL=132	NTRK2	intron	NTRK2:ENST00000277120.8:intron_variant:MODIFIER:intron2/18:c.212+15438C>T::,NTRK2:ENST00000304053.11:intron_variant:MODIFIER:intron1/12:c.212+15438C>T::,NTRK2:ENST00000323115.11:intron_variant:MODIFIER:intron2/16:c.212+15438C>T::,NTRK2:ENST00000359847.4:intron_variant:MODIFIER:intron3/13:c.212+15438C>T::,NTRK2:ENST00000376208.6:intron_variant:MODIFIER:intron4/15:c.212+15438C>T::,NTRK2:ENST00000376213.6:intron_variant:MODIFIER:intron2/17:c.212+15438C>T::,NTRK2:ENST00000395882.6:intron_variant:MODIFIER:intron4/14:c.212+15438C>T::,NTRK2:ENST00000685387.1:intron_variant:MODIFIER:intron2/11:c.212+15438C>T::,NTRK2:ENST00000685720.1:intron_variant:MODIFIER:intron2/14:c.212+15438C>T::,NTRK2:ENST00000686259.1:intron_variant:MODIFIER:intron3/18:c.212+15438C>T::,NTRK2:ENST00000686322.1:intron_variant:MODIFIER:intron1/11:c.-257+14227C>T::,NTRK2:ENST00000686324.1:intron_variant:MODIFIER:intron2/18:c.212+15438C>T::,NTRK2:ENST00000686443.1:intron_variant:MODIFIER:intron2/13:c.212+15438C>T::,NTRK2:ENST00000686496.1:intron_variant:MODIFIER:intron4/19:c.212+15438C>T::,NTRK2:ENST00000686542.1:intron_variant:MODIFIER:intron4/14:c.212+15438C>T::,NTRK2:ENST00000687148.1:intron_variant:MODIFIER:intron1/11:c.212+15438C>T::,NTRK2:ENST00000687386.1:intron_variant:MODIFIER:intron2/16:c.212+15438C>T::,NTRK2:ENST00000687596.1:intron_variant:MODIFIER:intron2/12:c.212+15438C>T::,NTRK2:ENST00000687636.1:intron_variant:MODIFIER:intron3/15:c.212+15438C>T::,NTRK2:ENST00000688013.1:intron_variant:MODIFIER:intron2/12:c.212+15438C>T::,NTRK2:ENST00000689301.1:intron_variant:MODIFIER:intron1/16:c.-257+14227C>T::,NTRK2:ENST00000689685.1:intron_variant:MODIFIER:intron3/13:c.212+15438C>T::,NTRK2:ENST00000689815.1:intron_variant:MODIFIER:intron4/14:c.212+15438C>T::,NTRK2:ENST00000690281.1:intron_variant:MODIFIER:intron2/12:c.212+15438C>T::,NTRK2:ENST00000691415.1:intron_variant:MODIFIER:intron2/12:c.212+15438C>T::,NTRK2:ENST00000691788.1:intron_variant:MODIFIER:intron2/17:c.212+15438C>T::,NTRK2:ENST00000692181.1:intron_variant:MODIFIER:intron4/19:c.212+15438C>T::,NTRK2:ENST00000692389.1:intron_variant:MODIFIER:intron4/14:c.212+15438C>T::,NTRK2:ENST00000692473.1:intron_variant:MODIFIER:intron1/17:c.-257+14227C>T::,NTRK2:ENST00000692506.1:intron_variant:MODIFIER:intron4/14:c.212+15438C>T::,NTRK2:ENST00000692762.1:intron_variant:MODIFIER:intron4/14:c.212+15438C>T::,NTRK2:ENST00000692804.1:intron_variant:MODIFIER:intron4/11:c.212+15438C>T::,NTRK2:ENST00000693109.1:intron_variant:MODIFIER:intron4/14:c.212+15438C>T::,NTRK2:ENST00000693127.1:intron_variant:MODIFIER:intron2/11:c.212+15438C>T::,NTRK2:ENST00000693384.1:intron_variant:MODIFIER:intron2/12:c.212+15438C>T::,NTRK2:ENST00000693539.1:intron_variant:MODIFIER:intron4/16:c.212+15438C>T::		600456_[GENE=NTRK2_PHENOS=Developmental and epileptic encephalopathy 58, 617830 (3), Autosomal dominant; Obesity, hyperphagia, and developmental delay, 613886 (3), Autosomal dominant]				rs997458517						-0.0900	1.98				0		107	SomaticAndTreatment,WES_ZPM			0	0	0 / 0							NTRK2 (inh=AD oe_syn=1.02 oe_mis=0.52 oe_lof=0.02)									na	na	.	.	123.03	65.2
chr9	136503194	136503194	C	A	0.4076	822	0	499		QUAL=874	NOTCH1	stop_gained	NOTCH1:ENST00000680133.1:stop_gained:HIGH:exon26/33:c.5041G>T:p.Glu1681Ter:PF07684 [NOTCH protein],NOTCH1:ENST00000651671.1:stop_gained:HIGH:exon27/34:c.5155G>T:p.Glu1719Ter:PF07684 [NOTCH protein],NOTCH1:ENST00000680218.1:stop_gained:HIGH:exon27/34:c.5035G>T:p.Glu1679Ter:PF07684 [NOTCH protein],NOTCH1:ENST00000680668.1:stop_gained:HIGH:exon26/33:c.5041G>T:p.Glu1681Ter:PF07684 [NOTCH protein],NOTCH1:ENST00000680778.1:stop_gained:HIGH:exon13/20:c.2752G>T:p.Glu918Ter:PF07684 [NOTCH protein]	regulatory_region_variant:CTCF_binding_site	190198_[GENE=NOTCH1_PHENOS=Adams-Oliver syndrome 5, 616028 (3), Autosomal dominant; Aortic valve disease 1, 109730 (3), Autosomal dominant]										3.5530	46.00			COSV99490401	0		0		LIKELY_ONCOGENIC		0	0	0 / 0							NOTCH1 (inh=AD oe_syn=1.17 oe_mis=0.76 oe_lof=0.05)	NOTCH1	COSV99490401			3				0	0				
chr12	61231953	61231953	T	C	0.0323	218	0	110	freq-tum;off-target	QUAL=74		non_coding_transcript_exon	:ENST00000548612.1:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.985A>G::												-0.2000	3.52						0				0	0	0 / 0																na	na	1	0.00	0.00	.
chr12	95787566	95787566	G	A	0.2403	156	0	145	off-target	QUAL=175	NTN4	intron	NTN4:ENST00000343702.9:intron_variant:MODIFIER:intron1/9:c.56-98C>T::,NTN4:ENST00000344911.8:intron_variant:MODIFIER:intron2/10:c.-56-98C>T::,NTN4:ENST00000538383.5:intron_variant:MODIFIER:intron1/9:c.-56-98C>T::,NTN4:ENST00000553059.1:intron_variant:MODIFIER:intron1/8:c.56-98C>T::,NTN4:ENST00000674345.1:intron_variant:MODIFIER:intron1/9:c.56-98C>T::												1.0090	5.43				0		1	SomaticAndTreatment			0	0	0 / 0							NTN4 (inh=n/a oe_syn=0.92 oe_mis=0.74 oe_lof=0.17), SNRPF-DT (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a), RNU6-247P (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)									na	na	.	.	5.82	6.2
chr13	23334734	23334734	G	A	0.4412	453	0	363		QUAL=672	SACS	missense,intron	SACS:ENST00000382292.9:missense_variant:MODERATE:exon10/10:c.9142C>T:p.Arg3048Cys:,SACS:ENST00000402364.1:missense_variant:MODERATE:exon8/8:c.6892C>T:p.Arg2298Cys:,SACS:ENST00000423156.2:intron_variant:MODIFIER:intron9/9:c.2186-5250C>T::,SACS:ENST00000455470.6:intron_variant:MODIFIER:intron10/10:c.2432-5250C>T::,SACS:ENST00000682775.1:intron_variant:MODIFIER:intron9/9:c.2185+19051C>T::,SACS:ENST00000682944.1:missense_variant:MODERATE:exon11/11:c.9169C>T:p.Arg3057Cys:,SACS:ENST00000683210.1:intron_variant:MODIFIER:intron9/9:c.2185+19051C>T::,SACS:ENST00000683270.1:intron_variant:MODIFIER:intron9/9:c.6445+2688C>T::,SACS:ENST00000683367.1:intron_variant:MODIFIER:intron8/8:c.2177-5250C>T::,SACS:ENST00000683489.1:intron_variant:MODIFIER:intron10/10:c.*-4782C>T::,SACS:ENST00000683680.1:intron_variant:MODIFIER:intron11/11:c.*-4782C>T::,SACS:ENST00000684163.1:intron_variant:MODIFIER:intron9/9:c.2204-5250C>T::,SACS:ENST00000684385.1:intron_variant:MODIFIER:intron10/10:c.2221-5250C>T::,SACS:ENST00000684497.1:intron_variant:MODIFIER:intron9/9:c.2186-12090C>T::		604490_[GENE=SACS_PHENOS=Spastic ataxia, Charlevoix-Saguenay type, 270550 (3), Autosomal recessive]				rs775533946	0.0001		0,.	3	152085	3.3850	27.60	0.62		COSV105319754	0		1	SomaticAndTreatment	UNCERTAIN_SIGNIFICANCE		0	0	0 / 0							SACS (inh=AR oe_syn=1.06 oe_mis=0.94 oe_lof=0.44)									na	na	26	0.62	34.38	6.4
chr13	32340199	32340222	TGATGTTAGTTTGGAAACTTCAGA	-	0.119	153	0	79		QUAL=79	BRCA2	inframe_deletion	BRCA2:ENST00000544455.6:inframe_deletion:MODERATE:exon11/27:c.5845_5868del:p.Asp1949_Asp1956del:,BRCA2:ENST00000380152.8:inframe_deletion:MODERATE:exon11/27:c.5845_5868del:p.Asp1949_Asp1956del:		600185_[GENE=BRCA2_PHENOS=Fanconi anemia, complementation group D1, 605724 (3), Autosomal recessive; {Glioblastoma 3}, 613029 (3), Autosomal recessive; {Medulloblastoma}, 155255 (3), Somatic mutation, Autosomal dominant, Autosomal recessive; {Prostate cancer}, 176807 (3), Somatic mutation, Autosomal dominant; {Breast-ovarian cancer, familial, 2}, 612555 (3), Autosomal dominant; {Breast cancer, male, susceptibility to}, 114480 (3), Somatic mutation, Autosomal dominant; {Pancreatic cancer 2}, 613347 (3); Wilms tumor, 194070 (3), Somatic mutation, Autosomal dominant]										1.4990			/2.6>2.1/0.0>0.0		0		0		UNCERTAIN_SIGNIFICANCE		0	0	0 / 0							BRCA2 (inh=AR+AD oe_syn=0.99 oe_mis=1.09 oe_lof=0.51)									0	1	1	1.00	12.80	0.1
chr13	49890561	49890561	-	G	1	4	0	3	depth-tum;depth-nor;off-target	QUAL=1	CTAGE10P,RNY4P30	upstream_gene	CTAGE10P:ENST00000318353.2:upstream_gene_variant:MODIFIER::::,RNY4P30:ENST00000410216.1:upstream_gene_variant:MODIFIER::::						rs34893433	0.2020		3171,.	24368	121352		2.07						3	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							RNY4P30 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a), CTAGE10P (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)									na,na	na,na	0	0.00	0.00	.
chr14	18692037	18692037	A	C	0.0826	349	0.0403	253	freq-nor;off-target	QUAL=49	RPL22P20	non_coding_transcript_exon	RPL22P20:ENST00000484916.1:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.6A>C::							0.0000		0,.	0	148526	-2.9720	1.17						10	Novartis,SomaticAndTreatment			0	12	0 / 2							RPL22P20 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)									na	na	1	0.00	0.00	.
chr14	68790575	68790575	A	C	0.1134	201	0.0141	142	off-target	QUAL=76	ZFP36L1	intron	ZFP36L1:ENST00000336440.3:intron_variant:MODIFIER:intron1/2:c.58-83T>G::,ZFP36L1:ENST00000439696.3:intron_variant:MODIFIER:intron1/1:c.58-83T>G::	regulatory_region_variant:promoter											1.1720	11.00				0		14	Novartis,SomaticAndTreatment,practical_training			0	1	0 / 0							ZFP36L1 (inh=n/a oe_syn=0.95 oe_mis=0.51 oe_lof=0.13)									na	na	.	.	453.93	30.5
chr15	92945865	92945865	G	A	0.0446	272	0	132	freq-tum	QUAL=82	CHD2	missense&splice_region	CHD2:ENST00000394196.9:missense_variant&splice_region_variant:MODERATE:exon11/39:c.1198G>A:p.Ala400Thr:PF00385 [Chromo (CHRromatin Organisation MOdifier) domain],CHD2:ENST00000420239.7:missense_variant&splice_region_variant:MODERATE:exon11/13:c.1198G>A:p.Ala400Thr:PF00385 [Chromo (CHRromatin Organisation MOdifier) domain],CHD2:ENST00000626782.2:missense_variant&splice_region_variant:MODERATE:exon10/12:c.1237G>A:p.Ala413Thr:PF00385 [Chromo (CHRromatin Organisation MOdifier) domain],CHD2:ENST00000626874.2:missense_variant&splice_region_variant:MODERATE:exon11/38:c.1198G>A:p.Ala400Thr:PF00385 [Chromo (CHRromatin Organisation MOdifier) domain],CHD2:ENST00000628375.2:missense_variant&splice_region_variant:MODERATE:exon10/11:c.1090G>A:p.Ala364Thr:PF00385 [Chromo (CHRromatin Organisation MOdifier) domain]		602119_[GENE=CHD2_PHENOS=Developmental and epileptic encephalopathy 94, 615369 (3), Autosomal dominant]										6.0810	34.00	0.15	9.88>7.47				0				0	0	0 / 0							CHD2 (inh=AD oe_syn=0.95 oe_mis=0.53 oe_lof=0.03)									0	1	34	0.09	25.75	15.6
chr16	27134616	27134616	C	T	0.2308	26	0	14	depth-nor;off-target	QUAL=39	EEF1A1P38	intron&non_coding_transcript	EEF1A1P38:ENST00000567658.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron1/1:n.533+31G>A::					AluSp (SINE/Alu)							-0.5600	5.63						1	SomaticAndTreatment			0	0	0 / 0							EEF1A1P38 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)									na	na	1	0.00	0.00	.
chr16	34573041	34573041	G	C	0.3333	18	0	16	depth-tum;depth-nor;off-target	QUAL=36		intergenic	::intergenic_variant:MODIFIER::::							0.0044		0,.	399	91055		9.64						6	Novartis,SomaticAndTreatment			0	6	0 / 0																na	na	.	.	0.00	.
chr16	34587347	34587347	A	G	0.5	4	0	12	lt-3-reads;depth-tum;depth-nor;off-target;low_conf_region	QUAL=15		intergenic	::intergenic_variant:MODIFIER::::						rs1596983036	0.0027		0,.	28	10184	-0.9410	14.43						2	SomaticAndTreatment			0	0	0 / 0																na	na	.	.	0.00	.
chr16	89752035	89752035	T	G	0.0481	105	0	85	freq-tum;off-target	QUAL=61	FANCA	intron	FANCA:ENST00000389301.8:intron_variant:MODIFIER:intron31/42:c.3066+103A>C::,FANCA:ENST00000564475.6:intron_variant:MODIFIER:intron31/41:c.3066+103A>C::,FANCA:ENST00000568369.6:intron_variant:MODIFIER:intron31/42:c.3066+103A>C::,FANCA:ENST00000696287.1:intron_variant:MODIFIER:intron30/40:c.2937+103A>C::	regulatory_region_variant:CTCF_binding_site	607139_[GENE=FANCA_PHENOS=Fanconi anemia, complementation group A, 227650 (3), Autosomal recessive]			AluY (SINE/Alu)							-2.3900	0.66				0		108	20101I_0461_Stephan,Keyriched-1,Novartis,SomaticAndTreatment,practical_training			0	2	0 / 0							FANCA (inh=AR oe_syn=1.57 oe_mis=1.55 oe_lof=1.15)									0	1	.	.	6.05	0.9
chr17	40343036	40343036	C	A	0.0312	895	0	580	freq-tum	QUAL=182	RARA,RARA-AS1	intron,non_coding_transcript_exon	RARA:ENST00000254066.10:intron_variant:MODIFIER:intron2/8:c.179-5280C>A::,RARA:ENST00000394081.7:intron_variant:MODIFIER:intron1/7:c.163+169C>A::,RARA:ENST00000394086.7:intron_variant:MODIFIER:intron1/7:c.226+1421C>A::,RARA:ENST00000394089.6:intron_variant:MODIFIER:intron2/8:c.179-5280C>A::,RARA:ENST00000425707.7:intron_variant:MODIFIER:intron2/6:c.179-8874C>A::,RARA-AS1:ENST00000581080.1:non_coding_transcript_exon_variant:MODIFIER:exon1/3:n.101G>T::	regulatory_region_variant:promoter	180240_[GENE=RARA_PHENOS=Leukemia, acute promyelocytic, 612376 (1)]										-0.4660	0.88				0		0				0	0	0 / 0							RARA (inh=n/a oe_syn=0.99 oe_mis=0.49 oe_lof=0.10), RARA-AS1 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)									1,na	0,na	1	0.00	19.26	2.5
chr17	42704487	42704487	A	G	0.06	51	0	29	LowEVS;off-target	QUAL=31	EZH1	intron	EZH1:ENST00000415827.6:intron_variant:MODIFIER:intron18/20:c.1990+115T>C::,EZH1:ENST00000428826.7:intron_variant:MODIFIER:intron18/20:c.2017+115T>C::,EZH1:ENST00000585893.5:intron_variant:MODIFIER:intron17/19:c.1897+115T>C::,EZH1:ENST00000590078.5:intron_variant:MODIFIER:intron17/19:c.1807+115T>C::,EZH1:ENST00000592743.5:intron_variant:MODIFIER:intron17/19:c.2017+115T>C::		602346_[GENE=CNTNAP1_PHENOS=Lethal congenital contracture syndrome 7, 616286 (3), Autosomal recessive; Hypomyelinating neuropathy, congenital, 3, 618186 (3), Autosomal recessive]			AluSx1 (SINE/Alu)							-0.6170	2.04				0		165	SomaticAndTreatment,practical_training			0	0	0 / 0							CNTNAP1 (inh=AR oe_syn=0.91 oe_mis=0.70 oe_lof=0.30), EZH1 (inh=AD oe_syn=0.79 oe_mis=0.42 oe_lof=0.26), MIR6780A (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)									na	na	.	.	32.82	19.8
chr18	11852667	11852667	T	C	0.0251	370	0	156	freq-tum;off-target	QUAL=83	GNAL,CHMP1B,CHMP1B-AS1	intron,3'UTR,non_coding_transcript_exon	GNAL:ENST00000269162.9:intron_variant:MODIFIER:intron6/12:c.492-9728T>C::,GNAL:ENST00000334049.11:intron_variant:MODIFIER:intron5/11:c.723-9728T>C::,GNAL:ENST00000423027.8:intron_variant:MODIFIER:intron5/11:c.492-9728T>C::,CHMP1B:ENST00000526991.3:3_prime_UTR_variant:MODIFIER:exon1/1:c.*556T>C::,GNAL:ENST00000535121.5:intron_variant:MODIFIER:intron6/12:c.492-9728T>C::,CHMP1B-AS1:ENST00000586474.1:non_coding_transcript_exon_variant:MODIFIER:exon1/2:n.85A>G::	regulatory_region_variant:promoter	139312_[GENE=GNAL_PHENOS=Dystonia 25, 615073 (3), Autosomal dominant]										0.5640	7.33				0		0				0	0	0 / 0							GNAL (inh=AD oe_syn=0.94 oe_mis=0.38 oe_lof=0.04), CHMP1B (inh=n/a oe_syn=0.83 oe_mis=0.93 oe_lof=0.00), CHMP1B-AS1 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)									na,na,na	na,na,na	22	0.00	9.88	15.1
chr19	7116972	7116972	A	T	0.0992	170	0.0132	159	off-target	QUAL=55	INSR	3'UTR	INSR:ENST00000302850.10:3_prime_UTR_variant:MODIFIER:exon22/22:c.*84T>A::,INSR:ENST00000341500.9:3_prime_UTR_variant:MODIFIER:exon21/21:c.*84T>A::		147670_[GENE=INSR_PHENOS=Rabson-Mendenhall syndrome, 262190 (3), Autosomal recessive; Leprechaunism, 246200 (3), Autosomal recessive; Diabetes mellitus, insulin-resistant, with acanthosis nigricans, 610549 (3); Hyperinsulinemic hypoglycemia, familial, 5, 609968 (3), Autosomal dominant]										-0.0790	4.82				0		8	SomaticAndTreatment,WES_ZPM,practical_training			0	0	0 / 0							INSR (inh=AR+AD oe_syn=1.06 oe_mis=0.62 oe_lof=0.31)									na	na	5	0.00	25.83	5.8
chr19	35732130	35732130	C	T	0.0441	204	0	159	freq-tum	QUAL=88	KMT2B	missense	KMT2B:ENST00000420124.4:missense_variant:MODERATE:exon27/37:c.5660C>T:p.Ser1887Phe:,KMT2B:ENST00000673918.2:missense_variant:MODERATE:exon27/37:c.5594C>T:p.Ser1865Phe:		606834_[GENE=KMT2B_PHENOS=Intellectual developmental disorder, autosomal dominant 68, 619934 (3), Autosomal dominant; Dystonia 28, childhood-onset, 617284 (3), Autosomal dominant]				rs1270944810						4.2380	26.10	0.63			0.02		0				0	0	0 / 0							KMT2B (inh=AD oe_syn=1.22 oe_mis=0.76 oe_lof=0.03)									na	na	14	0.00	17.40	5.6
chr19	41120534	41120534	T	-	0.5714	18	0	11	depth-tum;depth-nor;off-target	QUAL=4	CYP2F1	intron	CYP2F1:ENST00000331105.7:intron_variant:MODIFIER:intron4/9:c.484+49del::						rs34650210	0.2618		5119,.	28451	109089	0.6290	0.41				0		6	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							CYP2F1 (inh=n/a oe_syn=0.91 oe_mis=1.00 oe_lof=0.81)									na	na	.	.	0.00	0.0
chr20	37403372	37403372	A	G	0.031	129	0	106	freq-tum	QUAL=34	SRC	missense	SRC:ENST00000358208.9:missense_variant:MODERATE:exon13/13:c.1655A>G:p.Asn552Ser:,SRC:ENST00000373558.2:missense_variant:MODERATE:exon12/12:c.1622A>G:p.Asn541Ser:,SRC:ENST00000373567.6:missense_variant:MODERATE:exon12/12:c.1604A>G:p.Asn535Ser:,SRC:ENST00000373578.7:missense_variant:MODERATE:exon14/14:c.1604A>G:p.Asn535Ser:,SRC:ENST00000692112.1:missense_variant:MODERATE:exon15/15:c.1604A>G:p.Asn535Ser:,SRC:ENST00000692423.1:missense_variant:MODERATE:exon15/15:c.1604A>G:p.Asn535Ser:		190090_[GENE=SRC_PHENOS=?Thrombocytopenia 6, 616937 (3), Autosomal dominant; Colon cancer, advanced, somatic, 114500 (3)]										7.3000	23.70	0.34			0		0				0	0	0 / 0							SRC (inh=AD oe_syn=0.91 oe_mis=0.40 oe_lof=0.08)									1	0	1	0.00	4.59	1.7
chr21	43094859	43094859	-	TG	0.525	271	0	75	off-target	QUAL=193	U2AF1	intron	U2AF1:ENST00000291552.9:intron_variant:MODIFIER:intron5/7:c.349-72_349-71insCA::,U2AF1:ENST00000380276.6:intron_variant:MODIFIER:intron5/7:c.349-72_349-71insCA::,U2AF1:ENST00000459639.5:intron_variant:MODIFIER:intron4/6:c.130-72_130-71insCA::						rs34227794											0.03		0				1	0	0 / 0							U2AF1 (inh=AR+AD oe_syn=0.89 oe_mis=0.19 oe_lof=0.00)									1	0	.	.	2.07	20.2
chr21	43095394	43095394	T	C	0.4635	194	0	52	off-target	QUAL=135	U2AF1	intron	U2AF1:ENST00000291552.9:intron_variant:MODIFIER:intron5/7:c.348+44A>G::,U2AF1:ENST00000380276.6:intron_variant:MODIFIER:intron5/7:c.348+44A>G::,U2AF1:ENST00000459639.5:intron_variant:MODIFIER:intron4/6:c.129+44A>G::						rs4920040						-2.2630	0.25			COSV52341882	0		0				1	0	0 / 0							U2AF1 (inh=AR+AD oe_syn=0.89 oe_mis=0.19 oe_lof=0.00)									1	0	.	.	2.07	20.2
chr21	43095575	43095575	T	C	0.5219	348	0	91	off-target	QUAL=248	U2AF1	intron	U2AF1:ENST00000291552.9:intron_variant:MODIFIER:intron4/7:c.250-39A>G::,U2AF1:ENST00000380276.6:intron_variant:MODIFIER:intron4/7:c.250-39A>G::,U2AF1:ENST00000459639.5:intron_variant:MODIFIER:intron3/6:c.31-39A>G::						rs2839634						-0.4030	4.80			COSV52341760	0.02		0				1	0	0 / 0							U2AF1 (inh=AR+AD oe_syn=0.89 oe_mis=0.19 oe_lof=0.00)									1	0	.	.	2.07	20.2
chr21	44229109	44229109	T	C	0.4425	469	0	160	off-target	QUAL=381	ICOSLG	intron,3'UTR	ICOSLG:ENST00000344330.9:intron_variant:MODIFIER:intron6/6:c.898+945A>G::,ICOSLG:ENST00000400377.4:intron_variant:MODIFIER:intron5/5:c.548-65A>G::,ICOSLG:ENST00000400379.8:3_prime_UTR_variant:MODIFIER:exon6/6:c.*421A>G::,ICOSLG:ENST00000407780.8:intron_variant:MODIFIER:intron6/6:c.899-65A>G::,ICOSLG:ENST00000643466.2:intron_variant:MODIFIER:intron6/6:c.898+945A>G::,ICOSLG:ENST00000700352.1:intron_variant:MODIFIER:intron7/7:c.776-65A>G::,ICOSLG:ENST00000700355.1:3_prime_UTR_variant:MODIFIER:exon7/7:c.*421A>G::,ICOSLG:ENST00000700358.1:intron_variant:MODIFIER:intron5/5:c.644-65A>G::						rs7278940	0.0000		0,.	0	53918	-0.9620	1.79			COSV60263772	0	30463956	0				0	1	0 / 0							ICOSLG (inh=n/a oe_syn=1.11 oe_mis=0.77 oe_lof=0.51)									na	na	1	0.00	0.44	3.7
chr21	44229660	44229660	G	C	0.3654	274	0	41	low_conf_region	QUAL=125	ICOSLG	intron,missense	ICOSLG:ENST00000344330.9:intron_variant:MODIFIER:intron6/6:c.898+394C>G::,ICOSLG:ENST00000400377.4:intron_variant:MODIFIER:intron5/5:c.547+394C>G::,ICOSLG:ENST00000400379.8:missense_variant:MODERATE:exon6/6:c.1292C>G:p.Ser431Cys:,ICOSLG:ENST00000407780.8:intron_variant:MODIFIER:intron6/6:c.898+394C>G::,ICOSLG:ENST00000643466.2:intron_variant:MODIFIER:intron6/6:c.898+394C>G::,ICOSLG:ENST00000700352.1:intron_variant:MODIFIER:intron7/7:c.775+394C>G::,ICOSLG:ENST00000700355.1:intron_variant:MODIFIER:intron6/6:c.899-114C>G::,ICOSLG:ENST00000700358.1:intron_variant:MODIFIER:intron5/5:c.643+394C>G::						rs4818891	0.0001		0,.	1	60981	1.2790	5.29	0.03		COSV60264215	0		0				0	1	0 / 0							ICOSLG (inh=n/a oe_syn=1.11 oe_mis=0.77 oe_lof=0.51)									na	na	2	0.00	0.44	3.7
chr21	44229783	44229783	G	A	0.5524	744	0	190		QUAL=563	ICOSLG	intron,missense	ICOSLG:ENST00000344330.9:intron_variant:MODIFIER:intron6/6:c.898+271C>T::,ICOSLG:ENST00000400377.4:intron_variant:MODIFIER:intron5/5:c.547+271C>T::,ICOSLG:ENST00000400379.8:missense_variant:MODERATE:exon6/6:c.1169C>T:p.Pro390Leu:,ICOSLG:ENST00000407780.8:intron_variant:MODIFIER:intron6/6:c.898+271C>T::,ICOSLG:ENST00000643466.2:intron_variant:MODIFIER:intron6/6:c.898+271C>T::,ICOSLG:ENST00000700352.1:intron_variant:MODIFIER:intron7/7:c.775+271C>T::,ICOSLG:ENST00000700355.1:intron_variant:MODIFIER:intron6/6:c.899-237C>T::,ICOSLG:ENST00000700358.1:intron_variant:MODIFIER:intron5/5:c.643+271C>T::						rs4511811	0.0013		10,.	96	90614	0.9630	6.35	0.02		COSV60263498	0		0				0	2	0 / 0							ICOSLG (inh=n/a oe_syn=1.11 oe_mis=0.77 oe_lof=0.51)									na	na	1	0.00	0.44	3.7
chr21	44229895	44229895	A	G	0.4939	1416	0	325	low_conf_region	QUAL=882	ICOSLG	intron,missense	ICOSLG:ENST00000344330.9:intron_variant:MODIFIER:intron6/6:c.898+159T>C::,ICOSLG:ENST00000400377.4:intron_variant:MODIFIER:intron5/5:c.547+159T>C::,ICOSLG:ENST00000400379.8:missense_variant:MODERATE:exon6/6:c.1057T>C:p.Trp353Arg:,ICOSLG:ENST00000407780.8:intron_variant:MODIFIER:intron6/6:c.898+159T>C::,ICOSLG:ENST00000643466.2:intron_variant:MODIFIER:intron6/6:c.898+159T>C::,ICOSLG:ENST00000700352.1:intron_variant:MODIFIER:intron7/7:c.775+159T>C::,ICOSLG:ENST00000700355.1:intron_variant:MODIFIER:intron6/6:c.898+159T>C::,ICOSLG:ENST00000700358.1:intron_variant:MODIFIER:intron5/5:c.643+159T>C::						rs4568033	0.0925		2096,.	1969	60453	-0.5580	2.67	0.01		COSV60263272	0.01		5	Novartis,SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							ICOSLG (inh=n/a oe_syn=1.11 oe_mis=0.77 oe_lof=0.51)									na	na	2	0.00	0.44	3.7
chr21	44229965	44229965	T	C	0.5017	1161	0	293	low_conf_region	QUAL=597	ICOSLG	intron,synonymous	ICOSLG:ENST00000344330.9:intron_variant:MODIFIER:intron6/6:c.898+89A>G::,ICOSLG:ENST00000400377.4:intron_variant:MODIFIER:intron5/5:c.547+89A>G::,ICOSLG:ENST00000400379.8:synonymous_variant:LOW:exon6/6:c.987A>G:p.Gln329=:,ICOSLG:ENST00000407780.8:intron_variant:MODIFIER:intron6/6:c.898+89A>G::,ICOSLG:ENST00000643466.2:intron_variant:MODIFIER:intron6/6:c.898+89A>G::,ICOSLG:ENST00000700352.1:intron_variant:MODIFIER:intron7/7:c.775+89A>G::,ICOSLG:ENST00000700355.1:intron_variant:MODIFIER:intron6/6:c.898+89A>G::,ICOSLG:ENST00000700358.1:intron_variant:MODIFIER:intron5/5:c.643+89A>G::						rs13052840	0.0284		348,.	1131	62489	-0.1830	8.96			COSV60263420	0.1		2	Novartis			137	5	19 / 1							ICOSLG (inh=n/a oe_syn=1.11 oe_mis=0.77 oe_lof=0.51)									na	na	1	0.00	0.44	3.7
chr21	44230126	44230126	T	C	0.5167	217	0	69	off-target	QUAL=185	ICOSLG	intron	ICOSLG:ENST00000344330.9:intron_variant:MODIFIER:intron5/6:c.863-37A>G::,ICOSLG:ENST00000400377.4:intron_variant:MODIFIER:intron4/5:c.512-37A>G::,ICOSLG:ENST00000400379.8:intron_variant:MODIFIER:intron5/5:c.863-37A>G::,ICOSLG:ENST00000407780.8:intron_variant:MODIFIER:intron5/6:c.863-37A>G::,ICOSLG:ENST00000643466.2:intron_variant:MODIFIER:intron5/6:c.863-37A>G::,ICOSLG:ENST00000700352.1:intron_variant:MODIFIER:intron6/7:c.740-37A>G::,ICOSLG:ENST00000700355.1:intron_variant:MODIFIER:intron5/6:c.863-37A>G::,ICOSLG:ENST00000700358.1:intron_variant:MODIFIER:intron4/5:c.608-37A>G::						rs2236668	0.0001		1,.	8	70236	-4.4170	0.03			COSV60263568	0	30423114,31782165,27216775	0				1	1	0 / 0							ICOSLG (inh=n/a oe_syn=1.11 oe_mis=0.77 oe_lof=0.51)									na	na	.	.	0.44	3.7
chr21	44230202	44230202	A	G	0.4286	43	0	16	depth-nor;off-target	QUAL=30	ICOSLG	intron	ICOSLG:ENST00000344330.9:intron_variant:MODIFIER:intron5/6:c.863-113T>C::,ICOSLG:ENST00000400377.4:intron_variant:MODIFIER:intron4/5:c.512-113T>C::,ICOSLG:ENST00000400379.8:intron_variant:MODIFIER:intron5/5:c.863-113T>C::,ICOSLG:ENST00000407780.8:intron_variant:MODIFIER:intron5/6:c.863-113T>C::,ICOSLG:ENST00000643466.2:intron_variant:MODIFIER:intron5/6:c.863-113T>C::,ICOSLG:ENST00000700352.1:intron_variant:MODIFIER:intron6/7:c.740-113T>C::,ICOSLG:ENST00000700355.1:intron_variant:MODIFIER:intron5/6:c.863-113T>C::,ICOSLG:ENST00000700358.1:intron_variant:MODIFIER:intron4/5:c.608-113T>C::						rs4818892	0.0239		310,.	898	62010	-1.9010	0.50				0.01		1	SomaticAndTreatment			5	4	1 / 0							ICOSLG (inh=n/a oe_syn=1.11 oe_mis=0.77 oe_lof=0.51)									na	na	.	.	0.44	3.7
chr22	11625663	11625663	C	T	0.0727	168	0	147	LowEVS;off-target	QUAL=90		intergenic	::intergenic_variant:MODIFIER::::	regulatory_region_variant:open_chromatin_region					rs1449666615	0.0001		0,.	7	152295	5.0530	8.94						1	SomaticAndTreatment			0	1	0 / 0																na	na	.	.	0.00	.
chr22	15627869	15627869	C	A	0.1043	115	0	77	LowEVS;off-target	QUAL=80	NF1P6	intron&non_coding_transcript	NF1P6:ENST00000426025.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron4/10:n.602-153G>T::												-1.0620	0.51						1	SomaticAndTreatment			0	0	0 / 0							NF1P6 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)									na	na	1	0.00	0.00	.
chr22	20993700	20993700	C	T	0.0229	355	0	313	freq-tum	QUAL=76	LZTR1	synonymous	LZTR1:ENST00000646124.2:synonymous_variant:LOW:exon12/21:c.1299C>T:p.Tyr433=:,LZTR1:ENST00000700578.1:synonymous_variant:LOW:exon12/20:c.1299C>T:p.Tyr433=:		600574_[GENE=LZTR1_PHENOS=Noonan syndrome 2, 605275 (3), Autosomal recessive; Noonan syndrome 10, 616564 (3), Autosomal dominant; {Schwannomatosis-2, susceptibility to}, 615670 (3), Autosomal dominant]	1620494 [likely benign DISEASE=not provided];			rs148969689	0.0001		0,.	8	152198	-3.9280	0.14			COSV53147831	0.02		0				0	2	0 / 0							LZTR1 (inh=AR+AD oe_syn=1.07 oe_mis=0.93 oe_lof=2.28)	LZTR1	COSV53147831			Other				0	1	1	0.00	2.83	3.4
chr22	23220513	23220513	C	T	0.0156	709	0	666	freq-tum	QUAL=119	BCR	intron	BCR:ENST00000305877.13:intron_variant:MODIFIER:intron1/22:c.1280-33286C>T::,BCR:ENST00000359540.7:intron_variant:MODIFIER:intron1/21:c.1280-33286C>T::		151410_[GENE=BCR_PHENOS=Leukemia, chronic myeloid, Philadelphia chromosome positive, somatic, 608232 (4); Leukemia, acute lymphocytic, Philadelphia chromosome positive, somatic, 613065 (4)]				rs1002193864						-0.0390	6.41				0		0				0	0	0 / 0							BCR (inh=n/a oe_syn=1.13 oe_mis=0.91 oe_lof=0.17)									0	0	.	.	13.76	5.6
chr22	29287415	29287415	T	C	0.0446	116	0	112	freq-tum	QUAL=71	EWSR1	intron	EWSR1:ENST00000331029.11:intron_variant:MODIFIER:intron7/14:c.793+281T>C::,EWSR1:ENST00000332035.10:intron_variant:MODIFIER:intron6/15:c.625+281T>C::,EWSR1:ENST00000332050.10:intron_variant:MODIFIER:intron7/16:c.793+281T>C::,EWSR1:ENST00000333395.10:intron_variant:MODIFIER:intron7/8:c.793+281T>C::,EWSR1:ENST00000397938.7:intron_variant:MODIFIER:intron7/16:c.793+281T>C::,EWSR1:ENST00000406548.5:intron_variant:MODIFIER:intron7/16:c.793+281T>C::,EWSR1:ENST00000414183.6:intron_variant:MODIFIER:intron8/17:c.811+281T>C::,EWSR1:ENST00000629659.2:intron_variant:MODIFIER:intron7/14:c.796+281T>C::		133450_[GENE=EWSR1_PHENOS=Neuroepithelioma, 612219 (3); Ewing sarcoma, 612219 (3)]			AluSq (SINE/Alu)							-0.0820	4.50				0		139	Novartis,SomaticAndTreatment,Twist_Exome_Test,practical_training			0	1	0 / 0							EWSR1 (inh=n/a oe_syn=1.16 oe_mis=0.64 oe_lof=0.10)									1	0	.	.	32.72	30.1
chr22	29294891	29294891	G	A	0.0625	66	0	62	LowEVS	QUAL=39	EWSR1	intron	EWSR1:ENST00000331029.11:intron_variant:MODIFIER:intron9/14:c.1051-1348G>A::,EWSR1:ENST00000332035.10:intron_variant:MODIFIER:intron10/15:c.997-1348G>A::,EWSR1:ENST00000332050.10:intron_variant:MODIFIER:intron11/16:c.1057-1348G>A::,EWSR1:ENST00000397938.7:intron_variant:MODIFIER:intron11/16:c.1165-1348G>A::,EWSR1:ENST00000406548.5:intron_variant:MODIFIER:intron11/16:c.1162-1348G>A::,EWSR1:ENST00000414183.6:intron_variant:MODIFIER:intron12/17:c.1180-1348G>A::,EWSR1:ENST00000629659.2:intron_variant:MODIFIER:intron9/14:c.949-1348G>A::		133450_[GENE=EWSR1_PHENOS=Neuroepithelioma, 612219 (3); Ewing sarcoma, 612219 (3)]			AluSc (SINE/Alu)	rs997081686	0.0001		0,.	8	150676	-1.9530	0.37				0		25	20101I_0461_Stephan,SomaticAndTreatment,WES_ZPM			0	5	0 / 0							EWSR1 (inh=n/a oe_syn=1.16 oe_mis=0.64 oe_lof=0.10)									1	0	.	.	32.72	30.1
chr22	42128818	42128818	-	C	0.2841	99	0.0492	123	freq-nor;off-target;low_conf_region	QUAL=72	CYP2D6,NDUFA6-DT	frameshift,intron&non_coding_transcript	CYP2D6:ENST00000359033.4:frameshift_variant:HIGH:exon3/8:c.478dup:p.Glu160GlyfsTer43:PF00067 [Cytochrome P450],NDUFA6-DT:ENST00000439129.5:intron_variant&non_coding_transcript_variant:MODIFIER:intron5/6:n.1718+3413dup::,CYP2D6:ENST00000645361.2:frameshift_variant:HIGH:exon4/9:c.631dup:p.Glu211GlyfsTer43:PF00067 [Cytochrome P450]		124030_[GENE=CYP2D6_PHENOS={Codeine sensitivity}, 608902 (3), Autosomal recessive; {Debrisoquine sensitivity}, 608902 (3), Autosomal recessive]		CI994706 [CLASS=FP MUT=ALT PHEN="Poor metaboliser" GENE=CYP2D6];		rs763609904	0.0002		0,.	22	148688		18.47				0.51		0				1	147	0 / 23							NDUFA6-DT (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a), CYP2D6 (inh=AR oe_syn=1.43 oe_mis=1.32 oe_lof=1.64)									na,na	na,na	0	0.00	0.70	0.0
chrMT	12418	12418	A	-	0.3176	101	0	10	depth-nor;off-target	QUAL=25	MT-ND5	frameshift	MT-ND5:ENST00000361567.2:frameshift_variant:HIGH:exon1/1:c.89del:p.Asn30ThrfsTer7:			693440 [pathogenic DISEASE=Leber optic atrophy,Mitochondrial myopathy with reversible cytochrome C oxidase deficiency,Juvenile myopathy, encephalopathy, lactic acidosis AND stroke];			rs1603223730	0.0000					1.2450						20018511	4	SomaticAndTreatment			0	0	0 / 0							MT-CO1 (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-TS1 (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-TD (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-CO2 (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-TK (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-ATP8 (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-ATP6 (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-CO3 (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-TG (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-ND3 (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-TR (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-ND4L (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-ND4 (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-TH (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-TS2 (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-TL2 (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-ND5 (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-ND6 (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-TE (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-CYB (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-TT (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a), MT-TP (inh=MT oe_syn=n/a oe_mis=n/a oe_lof=n/a)	MT-ND5	COSV100677708			Other				na	na	7530	0.47	28,043.21	9100.7